Exam 2 Flashcards
(155 cards)
Our R&D team recently completed several studies using compound RZ43 that revealed beneficial effects on blood pressure in rats. What is the next legal step in order to perform testing in humans?
IND- allows them to ship in interstate commerce. .
What must be approved by the FDA before we may legally distribute a new drug in interstate commerce for patient use?
NDA
RZ43 was approved by the FDA for hypertension. Further rat studies show that the drug also shows promise in lowering cholesterol. Can we add this as an indication?
No, need supplemental new drug application
Fast forward 20+ years from the date the patent for RZ43 was originally filed. A
competitor company would like to manufacturer a generic version of RZ43. What type of application must they file with the FDA? What must they prove in this application?
aNDA (abbreviated NDA)
Need to prove bioequivalence only, allowed to be 80% the same.
Your company wants to maximize the time on the market for one of its drugs whose patent is expiring so it produces an “authorized generic” under a private label. What is the benefit of doing this?
They do not have to make an NDA, its basically just the brand drug.
FDAs purple book
Lists approved biological products with biosimilarity/interchangeability evaluations
First biosimilar FDA approved
Zarxio biosimilar to filgrastim by Amgen
FDA found no clinically meaningful difference in regards to structure/function, animal study data, human PK data, clinical immunogenicity data, clinical safety and efficacy data.
Does biosimilar mean interchangeable?
No
First interchangeable biosimilar product
Semglee interchangeable with Lantus
Can a biosimilar be substituted at the pharmacy without prescriber intervention?
No, within 5 business days after dispensing a biologic for which an interchangeable product is available, regardless of whether a substitution was made, the pharmacist shall communicate to the prescriber which was dispensed.
REMS
Risk Evaluation and Mitigation Strategies
Required risk management plans that use risk minimization strategies to ensure drug benefits outweigh the risks.
FDA can require before or after drug approval.
REMS may contain the following elements:
Medication guide
Communication plan
Elements to assure safe use (ETASU)
Implementation system
How is bioequivalence of generics determined?
Must be same in the following regards to the innovator drug:
(Pharmaceutically equivalent)
Active ingredient
Strength
Dosage form
Route of administration
Must have virtually the same rate and extent of absorption (must be within 80-125% of innovator drug)
Bioequivalence also refers to
Therapeutic equivalent
In the state of Ohio, bioequivalent drugs are referred to as:
generically equivalent drugs
A pharmacist may NOT select a generically equivalent drug if the prescriber:
Handwrites DAW
Indicates that the prescribed drug is medically necessary.
Cannot be preprinted, stamped, default
The pharmacist may not select a generically equivalent drug unless
Its price to the patient is less than or equal to the price of the brand drug
The pharmacist (or the pharmacist’s agent, assistant, or employee) MUST inform the patient (or the patient’s agent):
If a generically equivalent drug is available at a lower or equal cost.
Of the persons right to refuse the generically equivalent drug
(does not apply to any agency that will reimburse the pharmacy or for patients of a hospital or nursing home.
As a pharmacist, how can I determine if a product is generically equivalent?
Use the Orange Book
Orange book
Lists pharmaceutically equivalent drugs in a table and indicates if they are bioequivalent (aka therapeutically equivalent, or “generically equivalent”).
Drug products that the FDA considers to be therapeutically equivalent (generically
equivalent):
Those with no known or suspected bioequivalence problems.Designated AA, AN, AO, AP, or AT, depending on the dosage form.
Those with actual or potential bioequivalence problems that have been resolved
with adequate in vivo and/or in vitro evidence supporting bioequivalence. Designated AB.
Drug products that FDA at this time, considers NOT to be therapeutically equivalent (NOT generically equivalent)
Those for which actual or potential bioequivalence problems have not been
resolved by adequate evidence of bioequivalence. Often the problem is with
specific dosage forms rather than with the active ingredients. These are designated BC, BD, BE, BN, BP, BR, BS, BT, BX, or B*
In the state of Ohio, may a prescriber indicate that they do not want a drug
substituted by having 2 signature lines printed on their Rx pads – one line for
substitution permissible and one line that indicates “dispense as written”?
No, must be written out
If a prescriber writes DAW on a prescription but the patient requests the generic, may we legally perform the substitution?
No